Big Pharma is heading "off a cliff" and into "a black hole, " according to Wall Street.
For patients and Big Pharma alike, the prescription pill business is going to get ugly.
He uses these data to show how Big Pharma hides negative clinical trial results.
FORBES: PhRMA Is Not Effective in Improving the Image of the Pharma Industry
But much of the new effort comes from small biotech firms and Big Pharma defectors.
With big pharma in many cases absent from the game, biotech entered the field.
Many of the project leaders in offshore CROs are Big Pharma trained medicinal chemists.
Suddenly, several big pharma stocks are a lot more expensive than they were just weeks ago.
In coming years, things only look worse for Big Pharma--and better for health insurers and consumers.
They should watch out for some nagging symptoms that are still likely to bother Big Pharma.
Big Pharma is looking toward the biotech sector to feed the new pipeline for drug discovery.
FORBES: Forget The Fiscal Cliff: Deal Or No Deal These Sector ETFs Stand To Profit In 2013
The decision is also a big setback for the ever-greening strategy employed by big pharma.
FORBES: India Court Ruling Against Novartis Is Dark Omen For Big Pharma
This elegiac exchange occurred in the comments to my post, Big Pharma: What Went Wrong?
FORBES: Has Bad Management Destroyed Two Generations Of Drug Research?
His studies show that biotech companies are no better than Big Pharma at inventing drugs.
Big pharma routinely excludes suicidal patients from their tests of antidepressants and other drugs.
Such collaborations point to a shift in the growth strategy of big pharma firms.
He had consistently denied speculation that the company would be sold to big pharma.
Good news: U.S. regulators aren't slowing the introduction of copycat drugs to suit big pharma.
After these trials are done, the company hopes to sign up a big pharma partner.
There are rare disease drugs that Genzyme pioneered when Big Pharma refused to touch the area.
FORBES: Will Anyone Pay For The Next Generation of Stem Cell Cures?
The challenge here: Gilead competes not with biotech companies but with deep-pocketed Big Pharma.
Some 30% of big pharma's revenue now comes from products licensed from smaller biotech firms.
Basically, big pharma teams tend to get too seduced by the regulatory requirements for approval.
FORBES: Are We The Problem? The Role Of Poor Decision-Making In Stifling Drug Development
Despite their size and experience, big pharma are not that great at clinical trial design.
FORBES: Are We The Problem? The Role Of Poor Decision-Making In Stifling Drug Development
Big Pharma relies on blockbuster drugs for its profits but the supply is dwindling.
You have deals that were cut with Big Pharma, with the hospitals, with the doctors.
But the knowledge gained can benefit not just the big pharma sponsor, but patients as well.
FORBES: Is Big Pharma Utilizing Too Many Resources on Potential Blockbusters?
Is Shaywitz correct in his assertion that big pharma is placing too many large bets?
FORBES: Is Big Pharma Utilizing Too Many Resources on Potential Blockbusters?
Biotech often soars when big pharma languishes, as happened most recently during the early-2000 biotech bubble.
Big pharma is in a bad fix--and companies are increasingly turning to good cholesterol as the solution.
Special Offer: Kelley Wright has been buying into turnarounds in big pharma and telecom for several months now.
应用推荐